HS-IT201
/ Sino-Cell Biomed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 21, 2026
NICE-TIL (NKG2D-CAR/mbIL15/tEGFR-transduced TILs) and antitumor activity via dual TCR-HLA and NKG2D-NKG2DL killing pathways.
(ASCO 2026)
- "In summary, both in vitro data and clinical result suggest NICE-TIL may be an effective treatment for late-stage solid tumors."
First-in-human • IO biomarker • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • CD4 • CD8 • IL15 • NKG2D
1 to 1
Of
1
Go to page
1